ArticleCalcified tissue international1994
A novel synthetic vitamin D analogue, 2 beta-(3-hydroxypropoxy)1 alpha, 25-dihydroxyvitamin D3 (ED-71), increases bone mass by stimulating the bone formation in normal and ovariectomized rats.
Article in Calcified tissue international, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 87 citations in OpenAlex.
- Effects of Hyperlipidemia on Osseointegration of Dental Implants and Its Strategies.Journal of functional biomaterials · 2023Review
- Synthesis of C2-Alkoxy-Substituted 19-Nor Vitamin DBiomolecules · 2022Article
- Eldecalcitol, an active vitamin D analog, effectively prevents cyclophosphamide-induced osteoporosis in rats.Experimental and therapeutic medicine · 2019Article
- Eldecalcitol is more effective in promoting osteogenesis than alfacalcidol in Cyp27b1-knockout mice.PloS one · 2018Article
- Role of vitamin D in energy and bone metabolism in postmenopausal women with type 2 diabetes mellitus: A 6-month follow-up evaluation.Journal of diabetes investigation · 2018Article
- Histochemical examination of systemic administration of eldecalcitol combined with guided bone regeneration for bone defect restoration in rats.Journal of molecular histology · 2017Article
- Administration frequency as well as dosage of PTH are associated with development of cortical porosity in ovariectomized rats.Bone research · 2017Article
- Comparison of treatment effects of teriparatide and the bisphosphonate risedronate in an aged, osteopenic, ovariectomized rat model under various clinical conditions.Journal of bone and mineral metabolism · 2016Article
- Early Effects of Single and Low-Frequency Repeated Administration of Teriparatide, hPTH(1-34), on Bone Formation and Resorption in Ovariectomized Rats.Calcified tissue international · 2015Article
- Review
- Three-times-weekly administration of teriparatide improves vertebral and peripheral bone density, microarchitecture, and mechanical properties without accelerating bone resorption in ovariectomized rats.Calcified tissue international · 2015Article
- Effects of eldecalcitol on cortical bone response to mechanical loading in rats.BMC musculoskeletal disorders · 2015Article
- Vitamin D analogs and bone: preclinical and clinical studies with eldecalcitol.BoneKEy reports · 2014Review
- Osteoporosis treatment by a new active vitamin D3 compound, eldecalcitol, in Japan.Current osteoporosis reports · 2012Article
- Effect of ED-71, a New Active Vitamin D Analog, on Bone Formation in an Orthopedically Expanded Suture in Rats. A Histomorphometric Study.European journal of dentistry · 2009Article
- Vitamin D for the treatment of osteoporosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 1997Review
- Current and potential future drug treatments for osteoporosis.Annals of the rheumatic diseases · 1996Review
- Local bone turnover in the metaphysis of the proximal tibia and the lumbar vertebra during the early periods after ovariectomy in rats.Calcified tissue international · 1996Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We performed dosing experiments to evaluate the bone mass increasing action of a novel, synthetic vitamin D derivative, 2 beta-(3-hydroxypropoxy)-1 alpha,25(OH)2D3 (ED-71), in normal and estrogen-deficient rats. The first experiment consisted of 31 Sprague-Dawley rats, 28 weeks of age. The second experiment consisted of 44 animals who were ovariectomized (OVX) or sham operated at the age of 12 weeks. ED-71 was given twice a week for the duration of 12 weeks. At the end of the experiments, serum chemistries were examined and lumbar vertebrae were assessed histomorphometrically. Serum alkaline-phosphatase levels tended to decrease by ED-71 administration in the first experiment and their elevated values after ovariectomy were also depressed by ED-71 in the second experiment. Serum osteocalcin levels, however, increased by the agent. In the first experiment, cancellous bone volume (BV/TV) increased dose dependently. Bone formation rates (BFR/BS) also increased. In the second experiment, BV/TV significantly decreased by ovariectomy and it increased in ED-71-treated groups, but not in 1 alpha-(OH)D3-treated group. BFR/BS increased by ED-71. Activation frequency did not decrease by ED-71 in either experiment. These data clearly demonstrated that ED-71 administration was capable of increasing the bone mass by stimulating bone formation in normal and estrogen-deficient rats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.